Kamada Ltd. (NASDAQ: KMDA) is a vertically integrated, global biopharmaceutical company specializing in the development, production, and commercialization of specialty plasma-derived protein therapeutics. Utilizing proprietary protein purification technologies, Kamada develops treatments for rare and severe conditions, including Alpha-1 Antitrypsin Deficiency and specialized immune globulins, alongside operating a robust commercial product distribution business across international markets.